Spanish biotechnology company developing a gene-therapy approach for Alzheimer’s disease based on a modified transcription factor (E2F4DN). Lead candidate TET-101 showed promising preclinical efficacy and safety; company is preparing a Clinical Trial Application (CTA) in Europe to move into first-in-human studies.
Investment Rounds
Capital activity and funding progression
| Amount | Date | Round |
|---|---|---|
| not disclosed | Dec, 2025 | unspecified |
Frequently Asked Questions
What industries does Tetraneuron operate in?
Tetraneuron operates in the following industries: biotechnology, healthcare, gene therapy, neurodegenerative disease.
When was Tetraneuron founded?
Tetraneuron was founded on 2025-12-10.
Who are the investors in Tetraneuron?
The investors in Tetraneuron are: Gimic Ventures.